Skip to main
GKOS

Glaukos (GKOS) Stock Forecast & Price Target

Glaukos (GKOS) Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 58%
Buy 33%
Hold 8%
Sell 0%
Strong Sell 0%

Bulls say

Glaukos is poised to experience significant growth and success thanks to its pioneering minimally invasive glaucoma surgery procedures, the success of its iStent trabecular micro-bypass stent, and its expanding product portfolio and comprehensive platform. The company's iDose TR travoprost intracameral implant for glaucoma and sustained release will likely see strong demand, and the recent survey data show encouraging approval trends for approval of the product. The potential for future competition in the cross-linking market and potential LCD impacts could be offset by the company's successful launch of Epioxa and growing revenue.

Bears say

Glaukos is facing potential challenges in the near future due to proposed LCD changes for their iDose TR product, which may significantly impact sales volumes. Additionally, the combined burden of requiring patients to fail two medications and SLT before being eligible for iDose TR treatment may limit the potential efficacy and reach of the product. This may lead to lower revenues and slower growth for the company. Furthermore, the high percentage of iDose TR volumes being performed concomitantly with cataract surgery may also be impacted by potential LCD changes, creating uncertainty for future revenue growth. Additionally, while the company's Epioxa product may provide some upside in the future, there are concerns about limited payor coverage and the prior authorization process for the product. Overall, these factors may lead to a potential decrease in revenue and performance for Glaukos in the coming years.

Glaukos (GKOS) has been analyzed by 12 analysts, with a consensus rating of Buy. 58% of analysts recommend a Strong Buy, 33% recommend Buy, 8% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Glaukos and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Glaukos (GKOS) Forecast

Analysts have given Glaukos (GKOS) a Buy based on their latest research and market trends.

According to 12 analysts, Glaukos (GKOS) has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $177, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $177, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Glaukos (GKOS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.